Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer

被引:99
作者
Hebbar, Mohamed
Wacrenier, Agnes
Desauw, Christophe
Romano, Olivier
Cattan, Stephane
Triboulet, Jean-Pierre
Pruvot, Francois-Rene
机构
[1] CHU Lille, Med Oncol Unit, Dept Med Oncol, F-59037 Lille, France
[2] CHU Lille, Dept Pathol, F-59037 Lille, France
[3] CHU Lille, Dept Hepatpgastroenterol, F-59037 Lille, France
[4] CHU Lille, Dept Digest & Gen Surg, F-59037 Lille, France
[5] CHU Lille, Dept Transplantat & Digest Surg, F-59037 Lille, France
关键词
cetuximab; colorectal cancer; epidermal growth factor receptor;
D O I
10.1097/01.cad.0000217425.44584.9f
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In patients with metastatic colorectal cancer, the use of cetuximab currently requires a documented tumoral epidermal growth factor receptor positivity. Responses to cetuximab, however, have been described in patients with epidermal growth factor receptor-negative tumors. We have used cetuximab in all eligible patients with metastatic colorectal cancer, whether their tumor expressed epidermal growth factor receptor or not. We assessed the cetuximab efficacy with regard to tumoral epidermal growth factor receptor expression. Twenty patients with metastatic colorectal cancer were treated off study with cetuximab and irinotecan after failure of oxaliplatin- and irinotecan-based regimens. Tumors were analyzed in all patients for epidermal growth factor receptor expression by immunohistochemistry. Tumors were positive for epidermal growth factor receptor in 12 cases and negative in eight cases. An objective response to cetuximab-based therapy was obtained in four patients (20%). Tumors of these four patients were negative for epidermal growth factor receptor expression. These results provide further evidence for the lack of usefulness of epidermal growth factor receptor detection by immunohistochemistry for cetuximab therapy in patients with metastatic colorectal cancer.
引用
收藏
页码:855 / 857
页数:3
相关论文
共 12 条
  • [1] Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections
    Atkins, D
    Reiffen, KA
    Tegtmeier, CL
    Winther, H
    Bonato, MS
    Störkel, S
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2004, 52 (07) : 893 - 901
  • [2] Pharmacological background of EGFR targeting
    Castillo, L
    Etienne-Grimaldi, MC
    Fischel, JL
    Formento, P
    Magné, N
    Milano, G
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (07) : 1007 - 1012
  • [3] Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Chung, KY
    Shia, J
    Kemeny, NE
    Shah, M
    Schwartz, GK
    Tse, A
    Hamilton, A
    Pan, D
    Schrag, D
    Schwartz, L
    Klimstra, DS
    Fridman, D
    Kelsen, DP
    Saltz, LB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 1803 - 1810
  • [4] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) : 337 - 345
  • [5] Lenz HJ, 2004, J CLIN ONCOL, V22, p247S
  • [6] Milani A, 2005, Comparison of the Dynamical Evolution of Planetary Systems, P1, DOI 10.1007/s10569-005-3314-7
  • [7] Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
    Moroni, M
    Veronese, S
    Benvenuti, S
    Marrapese, G
    Sartore-Bianchi, A
    Di Nicolantonio, F
    Gambacorta, M
    Siena, S
    Bardelli, A
    [J]. LANCET ONCOLOGY, 2005, 6 (05) : 279 - 286
  • [8] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    Saltz, LB
    Meropol, NJ
    Loehrer, PJ
    Needle, MN
    Kopit, J
    Mayer, RJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) : 1201 - 1208
  • [9] Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies
    Scartozzi, M
    Bearzi, I
    Berardi, R
    Mandolesi, A
    Fabris, G
    Cascinu, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) : 4772 - 4778
  • [10] Starling Naureen, 2005, Clin Colorectal Cancer, V5 Suppl 1, pS28, DOI 10.3816/CCC.2005.s.004